{"id":2770,"date":"2026-11-03T21:59:19","date_gmt":"2026-11-03T13:59:19","guid":{"rendered":"http:\/\/www.puriactives.com\/en\/?p=2770"},"modified":"2026-11-03T21:59:19","modified_gmt":"2026-11-03T13:59:19","slug":"puriactivespmt-100","status":"publish","type":"post","link":"http:\/\/www.puriactives.com\/en\/?p=2770","title":{"rendered":"PuriActives\u00aePMT-100"},"content":{"rendered":"
\n
\n

PuriActives\u00ae PMT-100 | Palmitoyl Methoxytryptamine<\/h1>\n

INCI: PALMITOYL METHOXYTRYPTAMINE\"\"<\/p>\n

A lipophilic active for skin conditioning and anti-aging formulations\"\"<\/p>\n

5-Methoxyindole \u00b7 Ethylamide linker \u00b7 C16 palmitoyl chain\"\"<\/p>\n<\/section>\n

Molecular structure, human studies reported in patents, and formulation applications\"\"<\/p>\n<\/section>\n

Product<\/strong> value<\/strong> and<\/strong> scientific<\/strong> evidence<\/strong>\"\"<\/p>\n

PMT-100: Evidence for topical use and formulation applications<\/h2>\n

Human and skin studies<\/h3>\n

A cream containing 1.5% PMT was studied in humans for four weeks. A separate experiment tracked the distribution of radiolabeled analogues in skin.\"\"<\/p>\n

Proposed mechanisms<\/h3>\n

Patents link PMT to skin surface conditioning and the biology of free 5-MT. The original cell study figures shown below concern free 5-MT.\"\"<\/p>\n

Formulation development<\/h3>\n

The powder has an HPLC assay of \u226598.0% and is suitable for oil-phase formulation development. Historical patents provide examples across several product formats.\"\"<\/p>\n

Greff D. WO1998006695A1, Examples 1 and 3. Janjetovic Z et al. J Pineal Res. 2014. DOI: 10.1111\/jpi.12146. PuriPharm technical documentation.\"\"<\/p>\n<\/section>\n

Product<\/strong> profile<\/strong> and<\/strong> molecular<\/strong> structure<\/strong>\"\"<\/p>\n

The C16 acyl chain distinguishes PMT structurally<\/h2>\n
\n
\n
\n\n\n\n\n\n\n\n\n
\n
Item\"\"<\/p>\n<\/section>\n<\/th>\n
\n
Product information\"\"<\/p>\n<\/section>\n<\/th>\n<\/tr>\n
\n
INCI\"\"<\/p>\n<\/section>\n<\/td>\n
\n
PALMITOYL METHOXYTRYPTAMINE\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Chemical name\"\"<\/p>\n<\/section>\n<\/td>\n
\n
N-Hexadecanoyl-5-methoxytryptamine\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Molecular formula \/ molar mass\"\"<\/p>\n<\/section>\n<\/td>\n
\n
C\u2082\u2087H\u2084\u2084N\u2082O\u2082 \/ 428.65 g\/mol\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
CAS \/ UNII\"\"<\/p>\n<\/section>\n<\/td>\n
\n
151922-15-5 \/ 2298R31N7A\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Physical form \/ assay\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Powder \/ \u226598.0% (HPLC)\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<\/figure>\n
\"\"<\/figure>\n

5-Methoxyindole + ethylamide linker + palmitoyl chain\"\"<\/p>\n

Free 5-MT: no acyl group; melatonin: C2 acetyl group; PMT: C16 palmitoyl group.\"\"<\/p>\n

PuriPharm technical documentation; NCATS: 2298R31N7A; Villano R, Di Marzo V. Front Chem. 2024. DOI: 10.3389\/fchem.2024.1436008, Scheme 5.\"\"<\/p>\n<\/section>\n

Evidence<\/strong> for<\/strong> topical<\/strong> use<\/strong> |<\/strong> Human<\/strong> study<\/strong>\"\"<\/p>\n

Four-week human study of a 1.5% PMT cream<\/h2>\n

WO1998006695A1, Example 3\"\"<\/p>\n

25<\/strong>\u00a0Female participants \u00b7\u00a032\u201359<\/strong>\u00a0Age (years) \u00b7\u00a04<\/strong> weeks<\/strong>\u00a0Study duration\"\"<\/p>\n<\/section>\n

Split-face comparison within each participant<\/h3>\n

A 1.5% N-palmitoyl-5-MT cream was applied to one side of the face and a placebo cream to the other. Participants were blinded to assignment.\"\"<\/p>\n

Outcomes: sebum measurements, stratum corneum hydration, firmness\/tension, clinical assessments, and self-assessments.\"\"<\/p>\n

Greff D. WO1998006695A1, Example 3, pp. 4\u20135 of the description.\"\"<\/p>\n<\/section>\n

Evidence<\/strong> for<\/strong> topical<\/strong> use<\/strong> |<\/strong> Human<\/strong> study<\/strong> results<\/strong>\"\"<\/p>\n

The patent reports increases in skin hydration and firmness<\/h2>\n

1.5% N-palmitoyl-5-MT cream; 25 women; 4 weeks.\"\"<\/p>\n

\n
\n
\n\n\n\n\n\n\n
\n
Outcome\"\"<\/p>\n<\/section>\n<\/th>\n
\n
Active cream side\"\"<\/p>\n<\/section>\n<\/th>\n
\n
Placebo side\"\"<\/p>\n<\/section>\n<\/th>\n<\/tr>\n
\n
Sebum reading\"\"<\/p>\n<\/section>\n<\/td>\n
\n
\u221227%\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Stable\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Skin hydration\"\"<\/p>\n<\/section>\n<\/td>\n
\n
+35%\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Numerical change not reported\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Firmness \/ tension\"\"<\/p>\n<\/section>\n<\/td>\n
\n
+31%\"\"<\/p>\n<\/section>\n<\/td>\n
\n
\u22122%\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<\/figure>\n

Adapted from Example 3. Values show changes from baseline. The source does not report variability measures or P values.\"\"<\/p>\n

Greff D. WO1998006695A1, Example 3, pp. 4\u20135 of the description.\"\"<\/p>\n<\/section>\n

Evidence<\/strong> for<\/strong> topical<\/strong> use<\/strong> |<\/strong> Skin<\/strong> distribution<\/strong>\"\"<\/p>\n

An ex vivo study tracked tracer distribution across skin layers<\/h2>\n

Example 1 compared radiolabeled 2-iodo derivatives in a Franz-type diffusion model.\"\"<\/p>\n

30 min, 1 h, 2 h, and 4 h\"\"<\/p>\n

Superficial tape strips \u2193Epidermis \u2193Dermis \u2193Receptor fluid\"\"<\/p>\n<\/section>\n

Radioactivity in the different layers was measured by sequential tape stripping, tissue separation, and scintillation counting.\"\"<\/p>\n

Test materials: \u00b9\u00b2\u2075I-labeled 2-iodomelatonin and 2-iodo-N-palmitoyl-5-methoxytryptamine.\"\"<\/p>\n

Greff D. WO1998006695A1, Example 1, pp. 3\u20134 of the description.\"\"<\/p>\n<\/section>\n

Evidence<\/strong> for<\/strong> topical<\/strong> use<\/strong> |<\/strong> Skin<\/strong> distribution<\/strong>\"\"<\/p>\n

The patent reports epidermal retention of the palmitoylated tracer<\/h2>\n
155-fold<\/strong>Epidermal radioactivity of the palmitoylated tracerCompared with the melatonin tracer in the patent experiment\"\"<\/p>\n<\/section>\n
\n
\n
\n\n\n\n\n\n\n
\n
Skin layer\"\"<\/p>\n<\/section>\n<\/th>\n
\n
Reported observation\"\"<\/p>\n<\/section>\n<\/th>\n<\/tr>\n
\n
Epidermis \/ deeper tape strips\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Palmitoylated tracer concentrated here\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Dermis \/ receptor fluid\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Very low radioactivity\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Superficial tape strips\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Most of the melatonin tracer remained here\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<\/figure>\n

The measurement time and variability for this ratio were not specified. The results describe tracer distribution in skin.\"\"<\/p>\n

Greff D. WO1998006695A1, Example 1, pp. 3\u20134 of the description.\"\"<\/p>\n<\/section>\n

Biological<\/strong> rationale<\/strong> |<\/strong> Mechanism<\/strong> proposed<\/strong> in<\/strong> the<\/strong> patent<\/strong>\"\"<\/p>\n

Regulation of keratinization as a proposed mechanism for skin surface care<\/h2>\n

The patent links lipophilic methoxytryptamine derivatives to the conditioning of keratinized surfaces.\"\"<\/p>\n

Topical<\/strong> contact<\/strong>The dissolved or dispersed active contacts the skin surface.\u2193Keratin<\/strong> properties<\/strong>The patent proposes an effect on keratin content or rigidity.\u2193Skin<\/strong> appearance<\/strong> and<\/strong> feel<\/strong>The intended effects are a smoother feel and improved surface appearance.\"\"<\/p>\n<\/section>\n

This mechanism was proposed in the patent. The source did not quantify keratin biomarkers or verify receptor activation.\"\"<\/p>\n

Poret JL. US20040022822A1, paragraphs 0021\u20130037 and Examples 1\u20134 and 7.\"\"<\/p>\n<\/section>\n

Biological<\/strong> rationale<\/strong> |<\/strong> Hypothetical<\/strong> conversion<\/strong> pathway<\/strong>\"\"<\/p>\n

The patent proposes that PMT may be converted to free 5-MT<\/h2>\n

The proposed pathway involves enzymatic deacylation in the skin.\"\"<\/p>\n

PMT<\/strong>\u00a0\u00b7 Palmitoylated molecule\u2193 Hypothetical amide bond hydrolysis5-MT<\/strong>\u00a0\u00b7 Free amine\"\"<\/p>\n<\/section>\n

Free 5-MT provides biological context<\/h3>\n

Subsequent experiments tested free 5-MT in human keratinocytes. The cited patent did not quantify the extent of PMT conversion to 5-MT in skin.\"\"<\/p>\n

Greff D. WO1998006695A1, pp. 1\u20132 of the description: proposed enzymatic release of 5-methoxytryptamine.\"\"<\/p>\n<\/section>\n

Free<\/strong> 5-MT<\/strong> |<\/strong> Human<\/strong> keratinocyte<\/strong> model<\/strong>\"\"<\/p>\n

5-MT reduced nitrite at a UVB dose of 25 mJ\/cm\u00b2<\/h2>\n
\n
\n
\"\"<\/div>\n<\/div>
\u200b<\/span><\/figcaption><\/figure>\n

Original Figure 3. HaCaT cells; 50 \u00b5M; 24 h pretreatment; measured 30 min after UVB exposure. Original groups, error bars, and statistical symbols are retained.\"\"<\/p>\n

Janjetovic Z et al. J Pineal Res. 2014;57:90\u2013102. DOI: 10.1111\/jpi.12146.\"\"<\/p>\n<\/section>\n

Free<\/strong> 5-MT<\/strong> |<\/strong> Human<\/strong> keratinocyte<\/strong> model<\/strong>\"\"<\/p>\n

5-MT reduced H\u2082O\u2082 at UVB doses of 25 and 50 mJ\/cm\u00b2<\/h2>\n
\n
\n
\"\"<\/div>\n<\/div>
\u200b<\/span><\/figcaption><\/figure>\n

Original Figure 4. HaCaT cells; 50 \u00b5M; 24 h pretreatment; measured 30 min after UVB exposure. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.\"\"<\/p>\n

Janjetovic Z et al. J Pineal Res. 2014;57:90\u2013102. DOI: 10.1111\/jpi.12146.\"\"<\/p>\n<\/section>\n

Free<\/strong> 5-MT<\/strong> |<\/strong> Human<\/strong> keratinocyte<\/strong> model<\/strong>\"\"<\/p>\n

5-MT increased reduced glutathione after UVB exposure<\/h2>\n
\n
\n
\n
\"\"<\/div>\n<\/div>\n<\/div>\n<\/figure>\n

Original Figure 5. HaCaT cells; 50 \u00b5M; 24 h pretreatment; measured 1 h after UVB exposure. * P < 0.05, ** P < 0.01, *** P < 0.001.\"\"<\/p>\n

Janjetovic Z et al. J Pineal Res. 2014;57:90\u2013102. DOI: 10.1111\/jpi.12146.\"\"<\/p>\n<\/section>\n

Free<\/strong> 5-MT<\/strong> |<\/strong> Human<\/strong> keratinocyte<\/strong> model<\/strong>\"\"<\/p>\n

5-MT reduced CPD staining at 25 mJ\/cm\u00b2<\/h2>\n
\n
\n
\"\"<\/div>\n<\/div>
\u200b<\/span><\/figcaption><\/figure>\n

Original Figure 7<\/h3>\n

Primary keratinocytes (HEKn); 50 \u00b5M; 24 h pretreatment; measured 3 h after UVB exposure.\"\"<\/p>\n

B: 25 mJ\/cm\u00b2, 5-MT P < 0.05; C: 50 mJ\/cm\u00b2, no significant difference for 5-MT.\"\"<\/p>\n

CPD: cyclobutane pyrimidine dimer.\"\"<\/p>\n

Janjetovic Z et al. J Pineal Res. 2014;57:90\u2013102. DOI: 10.1111\/jpi.12146.\"\"<\/p>\n<\/section>\n

Free<\/strong> 5-MT<\/strong> |<\/strong> Human<\/strong> keratinocyte<\/strong> model<\/strong>\"\"<\/p>\n

The comet assay showed less DNA damage with 5-MT<\/h2>\n
\n
\n
\"\"<\/div>\n<\/div>
\u200b<\/span><\/figcaption><\/figure>\n

Original Figure 8<\/h3>\n

HEKn cells; 50 \u00b5M; 24 h pretreatment; 200 mJ\/cm\u00b2 UVB; 3 h treatment after UVB exposure.\"\"<\/p>\n

5-MT reduced the mean tail moment versus the UVB control (P < 0.05).\"\"<\/p>\n

Janjetovic Z et al. J Pineal Res. 2014;57:90\u2013102. DOI: 10.1111\/jpi.12146.\"\"<\/p>\n<\/section>\n

Formulation<\/strong> development<\/strong> |<\/strong> Product<\/strong> concepts<\/strong>\"\"<\/p>\n

Topical studies inform three skin care concepts<\/h2>\n

Moisturizing lotion<\/h3>\n

For skin that feels dry. Combine PMT with humectants and emollients, then assess hydration and skin feel.\"\"<\/p>\n

Firming cream<\/h3>\n

For a firmer appearance. Use the patent study’s firmness measures to guide finished-product testing.\"\"<\/p>\n

Balancing facial lotion<\/h3>\n

For skin that feels oily. At the target use level, assess sebum, shine, and sensory comfort.\"\"<\/p>\n

Greff D. WO1998006695A1, Examples 1 and 3, pp. 3\u20135 of the description. PuriPharm Co. Ltd.: Palmitoyl Methoxytryptamine powder technical documentation.\"\"<\/p>\n<\/section>\n

Formulation<\/strong> development<\/strong> |<\/strong> Use<\/strong> levels<\/strong>\"\"<\/p>\n

Supplier use levels for initial formulation development<\/h2>\n
\n
\n
\n\n\n\n\n\n\n
\n
Context\"\"<\/p>\n<\/section>\n<\/th>\n
\n
Use level \/ concentration\"\"<\/p>\n<\/section>\n<\/th>\n
\n
Development purpose\"\"<\/p>\n<\/section>\n<\/th>\n<\/tr>\n
\n
Supplier: standard face cream\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.05\u20130.20%\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Initial formulation development\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Supplier: intensive face cream\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.20\u20130.50%\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Evaluate in the intended finished-product base\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Human patent study: Example 3\"\"<\/p>\n<\/section>\n<\/td>\n
\n
1.50% PMT\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Concentration used in the historical study\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\u524d\u63d2\u884c<\/span>\u540e\u63d2\u884c<\/span><\/div>\n<\/div>\n<\/figure>\n

PMT-100 is a product code. Calculate active content on the assay basis stated in the batch certificate of analysis (COA).\"\"<\/p>\n

PuriPharm Co. Ltd.: Palmitoyl Methoxytryptamine powder technical documentation. Greff D. WO1998006695A1, Examples 1 and 3, pp. 3\u20135 of the description.\"\"<\/p>\n<\/section>\n

Formulation<\/strong> development<\/strong> |<\/strong> Incorporation<\/strong> and<\/strong> compatibility<\/strong>\"\"<\/p>\n

Formulation integration and nanoencapsulated product support<\/h2>\n

Choose a suitable oil phase<\/h3>\n

The supplier lists heated cosmetic esters and lipids, including caprylic\/capric triglyceride, squalane, and C12-15 alkyl benzoate.\"\"<\/p>\n

Dissolve fully before emulsification<\/h3>\n

The technical documentation specifies 75\u201380 \u00b0C for dissolution. Fully dissolve the powder before combining the phases.\"\"<\/p>\n

Check the formula after cooling<\/h3>\n

Check for recrystallization, cloudiness, and texture changes in the complete formula and final packaging.\"\"<\/p>\n

Support for formulation challenges<\/h3>\n

PuriPharm offers NanoActive PMT, a nanoliposomal palmitoyl methoxytryptamine product, to help address formulation challenges.\"\"<\/p>\n

PuriPharm Co. Ltd.: PMT-100 technical documentation and NanoActive PMT supply information.\"\"<\/p>\n<\/section>\n

Formulation<\/strong> examples<\/strong> |<\/strong> Published<\/strong> patent<\/strong>\"\"<\/p>\n

Published PMT examples cover five cosmetic product formats<\/h2>\n
\n
\n
\n\n\n\n\n\n\n\n\n
\n
Example\"\"<\/p>\n<\/section>\n<\/th>\n
\n
Product format\"\"<\/p>\n<\/section>\n<\/th>\n
\n
PMT, % w\/w\"\"<\/p>\n<\/section>\n<\/th>\n<\/tr>\n
\n
1\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Skin care cream\"\"<\/p>\n<\/section>\n<\/td>\n
\n
2.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
2\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Skin serum\"\"<\/p>\n<\/section>\n<\/td>\n
\n
3.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
3\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Toner\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.50\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
4\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Cleanser\"\"<\/p>\n<\/section>\n<\/td>\n
\n
1.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
7\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Hair conditioner\"\"<\/p>\n<\/section>\n<\/td>\n
\n
1.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\u524d\u63d2\u884c<\/span>\u540e\u63d2\u884c<\/span><\/div>\n<\/div>\n<\/figure>\n

These historical formulas use concentrations reported separately from supplier use levels and the human study concentration.\"\"<\/p>\n

Poret JL. US20040022822A1, Examples 1\u20134 and 7. PMT concentration: % w\/w.\"\"<\/p>\n<\/section>\n

Patent<\/strong> Example<\/strong> 1<\/strong> |<\/strong> Original<\/strong> formula<\/strong> table<\/strong> (part<\/strong> 1)<\/strong>\"\"<\/p>\n

The cream example includes aqueous and lipid phases<\/h2>\n
\n
\n
\"\"<\/div>\n<\/div>
\u200b<\/span><\/figcaption><\/figure>\n

Editable transcription<\/h3>\n
\n
\n
\n\n\n\n\n\n\n\n\n\n\n\n
\n
Ingredient (original wording)\"\"<\/p>\n<\/section>\n<\/th>\n
\n
w\/w %\"\"<\/p>\n<\/section>\n<\/th>\n<\/tr>\n
\n
Water\"\"<\/p>\n<\/section>\n<\/td>\n
\n
53.47\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Allantoin\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.20\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Glycerin\"\"<\/p>\n<\/section>\n<\/td>\n
\n
3.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Methyl paraben\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.25\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Palmitoyl hydrolyzed wheat protein\"\"<\/p>\n<\/section>\n<\/td>\n
\n
1.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Triethanolamine\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.15\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Glycerin\/water\/PEG-8\/caprylyl glycol\/sodium polyacrylate\"\"<\/p>\n<\/section>\n<\/td>\n
\n
5.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Petrolatum\"\"<\/p>\n<\/section>\n<\/td>\n
\n
2.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\"\"<\/span><\/div>\n<\/div>\n<\/figure>\n

Editable transcription<\/h3>\n
\n
\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
Ingredient (original wording)\"\"<\/p>\n<\/section>\n<\/th>\n
\n
w\/w %\"\"<\/p>\n<\/section>\n<\/th>\n<\/tr>\n
\n
Squalane\"\"<\/p>\n<\/section>\n<\/td>\n
\n
4.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Butyl methoxy dibenzoylmethane\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.25\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Butylated hydroxy toluene\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.02\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Propyl paraben\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.05\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Octyl methoxycinnamate\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.75\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Diazolidinyl urea\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.15\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Sodium hyaluronate\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.01\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Tocopheryl acetate\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.30\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Sodium PCA\"\"<\/p>\n<\/section>\n<\/td>\n
\n
1.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Fragrance\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.30\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Cyclomethicone and dimethiconol\"\"<\/p>\n<\/section>\n<\/td>\n
\n
2.50\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\u524d\u63d2\u884c<\/span>\u540e\u63d2\u884c<\/span><\/div>\n<\/div>\n<\/figure>\n

The two portions of the original formula table are stacked in their original reading order. Original ingredient names and units are retained.\"\"<\/p>\n

Poret JL. US20040022822A1, Example 1, first and middle portions of the original table.\"\"<\/p>\n<\/section>\n

Patent<\/strong> Example<\/strong> 1<\/strong> |<\/strong> Original<\/strong> formula<\/strong> table<\/strong> (part<\/strong> 2)<\/strong>\"\"<\/p>\n

The original cream formula contains 2.00% PMT<\/h2>\n
\n
\n
\"\"<\/div>\n<\/div>
\u200b<\/span><\/figcaption><\/figure>\n

Editable transcription<\/h3>\n
\n
\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
Ingredient (original wording)\"\"<\/p>\n<\/section>\n<\/th>\n
\n
w\/w %\"\"<\/p>\n<\/section>\n<\/th>\n<\/tr>\n
\n
Behenyl alcohol\/arachidyl alcohol\/stearyl alcohol\"\"<\/p>\n<\/section>\n<\/td>\n
\n
3.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Coco-caprylate\/caprate\"\"<\/p>\n<\/section>\n<\/td>\n
\n
2.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Shorea stenoptera butter\"\"<\/p>\n<\/section>\n<\/td>\n
\n
5.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Isononyl isononanoate\"\"<\/p>\n<\/section>\n<\/td>\n
\n
5.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Pentaerythrityl tetraoctanoate\"\"<\/p>\n<\/section>\n<\/td>\n
\n
2.50\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Glyceryl behenate\"\"<\/p>\n<\/section>\n<\/td>\n
\n
2.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Polyacrylamide\/water\/C13-14 isoparaffin\/laureth-7\"\"<\/p>\n<\/section>\n<\/td>\n
\n
2.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Biosaccharide gum-1\/phenoxyethanol\/parabens\"\"<\/p>\n<\/section>\n<\/td>\n
\n
1.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Palmitoyl-methoxytryptamine\"\"<\/p>\n<\/section>\n<\/td>\n
\n
2.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Water\/propylene glycol\/hydrolyzed soy protein\/phenoxyethanol\/aloe barbadensis extract\/parabens\"\"<\/p>\n<\/section>\n<\/td>\n
\n
1.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Phenoxyethanol\/methyldibromo glutaronitrile\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.10\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\u524d\u63d2\u884c<\/span>\u540e\u63d2\u884c<\/span><\/div>\n<\/div>\n<\/figure>\n

A documented emulsion system<\/h3>\n

The continuation includes PMT, emollients, structuring ingredients, and preservatives.\"\"<\/p>\n

All original rows are retained, and the w\/w header is repeated for readability.\"\"<\/p>\n

Poret JL. US20040022822A1, Example 1, final portion of the original table.\"\"<\/p>\n<\/section>\n

Patent<\/strong> Example<\/strong> 3<\/strong> |<\/strong> Original<\/strong> formula<\/strong> table<\/strong>\"\"<\/p>\n

The toner example contains 0.50% PMT<\/h2>\n
\n
\n
\"\"<\/div>\n<\/div>
\u200b<\/span><\/figcaption><\/figure>\n

Editable transcription<\/h3>\n
\n
\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
Ingredient (original wording)\"\"<\/p>\n<\/section>\n<\/th>\n
\n
w\/w %\"\"<\/p>\n<\/section>\n<\/th>\n<\/tr>\n
\n
PPG-2 – Ceteareth-5\"\"<\/p>\n<\/section>\n<\/td>\n
\n
3.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Trideceth-9, PEG-5 Octanoate\"\"<\/p>\n<\/section>\n<\/td>\n
\n
2.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Menthol\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.01\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Fragrance\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.20\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Water\"\"<\/p>\n<\/section>\n<\/td>\n
\n
QS\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Sericin\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.05\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Hydrolyzed sweet almont protein\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.05\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Propylene glycol\"\"<\/p>\n<\/section>\n<\/td>\n
\n
4.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Preservatives\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.30\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Tetrasodium EDTA\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.09\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Benzophenone 4\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.05\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Diazolidinyl urea\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.25\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Colorants\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.01\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Palmitoyl methoxytryptamine\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.50\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\u524d\u63d2\u884c<\/span>\u540e\u63d2\u884c<\/span><\/div>\n<\/div>\n<\/figure>\n

QS = quantity sufficient.\"\"<\/p>\n

An aqueous system with solubilizers<\/h3>\n

The example combines water and propylene glycol with solubilizing ingredients.\"\"<\/p>\n

This is a historical formula. The patent does not report toner stability or efficacy in humans.\"\"<\/p>\n

Poret JL. US20040022822A1, Example 3, original formula table.\"\"<\/p>\n<\/section>\n

Patent<\/strong> Example<\/strong> 4<\/strong> |<\/strong> Original<\/strong> formula<\/strong> table<\/strong>\"\"<\/p>\n

The cleanser example contains 1.00% PMT<\/h2>\n
\n
\n
\"\"<\/div>\n<\/div>
\u200b<\/span><\/figcaption><\/figure>\n

Editable transcription<\/h3>\n
\n
\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
Ingredient (original wording)\"\"<\/p>\n<\/section>\n<\/th>\n
\n
w\/w %\"\"<\/p>\n<\/section>\n<\/th>\n<\/tr>\n
\n
Water\"\"<\/p>\n<\/section>\n<\/td>\n
\n
QS\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Preservatives\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.30\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Decyl glucoside\"\"<\/p>\n<\/section>\n<\/td>\n
\n
2.40\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Disodium lauroamphodiacetate\/sodium trideceth sulfate\/hexylene glycol\/isopropanol\"\"<\/p>\n<\/section>\n<\/td>\n
\n
12.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Fragrance\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.40\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Polyquaternium-10\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.06\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Polyquaternium-7\"\"<\/p>\n<\/section>\n<\/td>\n
\n
3.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Diazolidinyl urea\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.20\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Propylene glycol, primula veris\"\"<\/p>\n<\/section>\n<\/td>\n
\n
0.10\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Palmitoyl methoxytryptamine\"\"<\/p>\n<\/section>\n<\/td>\n
\n
1.00\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\u524d\u63d2\u884c<\/span>\u540e\u63d2\u884c<\/span><\/div>\n<\/div>\n<\/figure>\n

QS = quantity sufficient.\"\"<\/p>\n

A surfactant-based formula<\/h3>\n

The original formula combines cleansing ingredients with conditioning polymers.\"\"<\/p>\n

It provides an example for rinse-off formulation development.\"\"<\/p>\n

Poret JL. US20040022822A1, Example 4, original formula table.\"\"<\/p>\n<\/section>\n

Product<\/strong> quality<\/strong> |<\/strong> Powder<\/strong> ingredient<\/strong>\"\"<\/p>\n

Quality specifications for the powder<\/h2>\n
\n
\n
\n\n\n\n\n\n\n\n\n\n
\n
Item\"\"<\/p>\n<\/section>\n<\/th>\n
\n
Stated specification\"\"<\/p>\n<\/section>\n<\/th>\n
\n
Method\"\"<\/p>\n<\/section>\n<\/th>\n<\/tr>\n
\n
Appearance\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Off-white to pale yellow powder\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Visual inspection\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Odor\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Characteristic, mild\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Sensory inspection\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Assay\"\"<\/p>\n<\/section>\n<\/td>\n
\n
\u226598.0%\"\"<\/p>\n<\/section>\n<\/td>\n
\n
HPLC\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Loss on drying\"\"<\/p>\n<\/section>\n<\/td>\n
\n
\u22641.0%\"\"<\/p>\n<\/section>\n<\/td>\n
\n
105 \u00b0C, 2 h\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Heavy metals (as Pb)\"\"<\/p>\n<\/section>\n<\/td>\n
\n
\u226410 ppm\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Colorimetry\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Acid value\"\"<\/p>\n<\/section>\n<\/td>\n
\n
\u22642.0 mg KOH\/g\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Titration\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\u524d\u63d2\u884c<\/span>\u540e\u63d2\u884c<\/span><\/div>\n<\/div>\n<\/figure>\n

PuriPharm Co. Ltd.: Palmitoyl Methoxytryptamine powder technical documentation.\"\"<\/p>\n<\/section>\n

Product<\/strong> quality<\/strong> |<\/strong> Storage<\/strong> and<\/strong> microbiology<\/strong>\"\"<\/p>\n

Storage conditions and microbial limits<\/h2>\n
\n
\n
\n\n\n\n\n\n\n
\n
Microbiological parameter\"\"<\/p>\n<\/section>\n<\/th>\n
\n
Stated limit\"\"<\/p>\n<\/section>\n<\/th>\n<\/tr>\n
\n
Total colony count\"\"<\/p>\n<\/section>\n<\/td>\n
\n
\u22641000 CFU\/g\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Yeasts and molds\"\"<\/p>\n<\/section>\n<\/td>\n
\n
\u2264100 CFU\/g\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Not detected per gram\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\u524d\u63d2\u884c<\/span>\u540e\u63d2\u884c<\/span><\/div>\n<\/div>\n<\/figure>\n

24 months\"\"<\/p>\n

Stated shelf life under specified storage conditions\"\"<\/p>\n

Store tightly sealed in a cool, dry place. Long-term storage temperature: 2\u20138 \u00b0C.\"\"<\/p>\n

PuriPharm Co. Ltd.: Palmitoyl Methoxytryptamine powder technical documentation.\"\"<\/p>\n<\/section>\n

Formulation<\/strong> development<\/strong> |<\/strong> Testing<\/strong>\"\"<\/p>\n

Choose measures that match the product concept<\/h2>\n
\n
\n
\n\n\n\n\n\n\n\n\n
\n
Development focus\"\"<\/p>\n<\/section>\n<\/th>\n
\n
Suggested assessment\"\"<\/p>\n<\/section>\n<\/th>\n<\/tr>\n
\n
Incorporation and stability\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Assay, microscopy, precipitation, and physical stability\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Moisturizing performance\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Instrumental hydration testing against a matched vehicle\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Firm appearance and feel\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Defined instrumental measures and blinded ratings\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Oily skin feel\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Sebum measurements, shine, and sensory assessment\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n
\n
Finished-product tolerability\"\"<\/p>\n<\/section>\n<\/td>\n
\n
Tolerability and user experience under intended conditions of use\"\"<\/p>\n<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\u524d\u63d2\u884c<\/span>\u540e\u63d2\u884c<\/span><\/div>\n<\/div>\n<\/figure>\n

Use the same base formula, conditions of use, and assessment schedule for the active and vehicle control groups.\"\"<\/p>\n

Development recommendations draw on Greff D. WO1998006695A1, Example 3, and PuriPharm formulation documentation.\"\"<\/p>\n<\/section>\n

PuriPharm<\/strong> Co.<\/strong> Ltd.<\/strong>\"\"<\/p>\n

Developing PMT-100 skin care products together<\/h2>\n

Defined molecular structure; relevant topical research; powder format suited to formulation development.\"\"<\/p>\n

Technical inquiries<\/h3>\n

service@puripharm.com+86-572-2745768www.puriactives.com\"\"<\/p>\n

Contact PuriPharm for formulation support and to evaluate NanoActive PMT nanoliposomal palmitoyl methoxytryptamine. Inquiries about samples, specifications, and formulation testing are welcome.\"\"<\/p>\n

PuriPharm technical and supply documentation; Greff D. WO1998006695A1, Examples 1 and 3.\"\"<\/p>\n<\/section>\n

Appendix<\/strong> |<\/strong> Animal<\/strong> study<\/strong> of<\/strong> homologues<\/strong>\"\"<\/p>\n

Animal research provides context for the series of homologues<\/h2>\n

Experimental model<\/h3>\n

Mice received intraperitoneal injections of melatonin homologues followed 30 minutes later by 950 cGy photon irradiation.\"\"<\/p>\n

Published results<\/h3>\n

The abstract reported protective effects across the series, with the C6 and C8 amides showing the best survival outcomes.\"\"<\/p>\n

Scope of evidence<\/h3>\n

The indexed abstract provides no separate survival values for PMT and no topical skin outcomes. The study provides background for the N-acyl-5-MT series.\"\"<\/p>\n

Blickenstaff RT et al. J Pharm Sci. 1994;83:216\u2013218. DOI: 10.1002\/jps.2600830220. Villano R, Di Marzo V. Front Chem. 2024;12:1436008. DOI: 10.3389\/fchem.2024.1436008.\"\"<\/p>\n<\/section>\n<\/section>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PuriActives\u00ae PMT-100 | Palmitoyl Methoxytryptamine INCI […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[25],"tags":[],"_links":{"self":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/2770"}],"collection":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2770"}],"version-history":[{"count":1,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/2770\/revisions"}],"predecessor-version":[{"id":2782,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/2770\/revisions\/2782"}],"wp:attachment":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2770"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}